RNA THERAPEUTICS INC.

Biotech · Private

mRNA-based vaccines formulated in lipid nanoparticles for infectious diseases, initially targeting pan-COVID-19 protection

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$300K
Federal grants
$300K
1 award · 2024
Rank in peer group#52 of 392
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
40 pending

Capital timeline

2024FEDERAL ↑EQUITY ↓Cumulative $300K$300K
2024FEDERAL ↑EQUITY ↓Cumulative $300K$300K

Latest events

  • Federal grantHealth and Human S · Phase I · Development of a Pan-COVID-19 Vaccine Candidate$300K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 392 peers

Line = median

Biotech · Molecule

  • Federal grants#52 · top 13%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 40
  • PendingSingle-chain Zagotenemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsUSPTOApplication 18886969
  • PendingSingle-chain MEDI1341 Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsUSPTOApplication 18886978
  • PendingSingle-chain Ustekinumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsUSPTOApplication 18882532
Show all 40 patent records
  • Single-chain Zagotenemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 19, 2026 · Application 18886969Pending
  • Single-chain MEDI1341 Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 19, 2026 · Application 18886978Pending
  • Single-chain Ustekinumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 12, 2026 · Application 18882532Pending
  • Single-chain Trastuzumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 12, 2026 · Application 18830561Pending
  • Single-chain Tilavonemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 5, 2026 · Application 18822148Pending
  • Single-chain Tildrakizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 5, 2026 · Application 18822154Pending
  • Single-chain Teprotumumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 5, 2026 · Application 18821955Pending
  • Single-chain Solanezumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 5, 2026 · Application 18821862Pending
  • Single-chain Semorinemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 26, 2026 · Application 18815737Pending
  • Single-chain Secukinumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 26, 2026 · Application 18814492Pending
  • Single-chain Romosozumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 26, 2026 · Application 18814490Pending
  • Single-chain Risankizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 26, 2026 · Application 18812880Pending
  • Single-chain Romiplostim Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 26, 2026 · Application 18812982Pending
  • Single-chain Ravulizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 26, 2026 · Application 18811717Pending
  • Single-chain Ranibizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 19, 2026 · Application 18809181Pending
  • Single-chain Prasinezumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 19, 2026 · Application 18807943Pending
  • Single-chain Ocrelizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 19, 2026 · Application 18805486Pending
  • Single-chain Ofatumumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 19, 2026 · Application 18805506Pending
  • Single-chain Natalizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 19, 2026 · Application 18803347Pending
  • Single-chain Lecanemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 19, 2026 · Application 18803103Pending
  • Single-chain Infliximab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18801147Pending
  • Single-chain Ixekizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18801197Pending
  • Single-chain Gosuranemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18800035Pending
  • Single-chain Guselkumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18800039Pending
  • Single-chain Gantenerumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18800034Pending
  • Single-chain Exidavnemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18798688Pending
  • Single-chain Eculizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18796212Pending
  • Single-chain Dupilumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18796151Pending
  • Single-chain Donanemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18795122Pending
  • Single-chain Crenezumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18793837Pending
  • Single-chain Cetuximab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18792501Pending
  • Single-chain Cinpanemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18792521Pending
  • Single-chain Canakinumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18791419Pending
  • Single-chain Brolucizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18791404Pending
  • Single-chain Bevacizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18789439Pending
  • Single-chain Belimumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsJan 29, 2026 · Application 18788021Pending
  • Single-chain Aflibercept Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsJan 29, 2026 · Application 18786456Pending
  • Single-chain Alemtuzumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsJan 29, 2026 · Application 18786461Pending
  • Single-chain Basiliximab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsJan 29, 2026 · Application 18786478Pending
  • Single-chain Aducanumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsJan 22, 2026 · Application 18780444Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .